Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Assets (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Other Non-Current Assets for 13 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 16.79% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Dec 2025, down 16.79%, and an annual FY2025 reading of $3.9 million, down 16.79% over the prior year.
  • Other Non-Current Assets was $3.9 million for Q4 2025 at Agios Pharmaceuticals, roughly flat from $3.9 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $53.4 million in Q1 2021 and bottomed at $2.9 million in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $6.5 million, with a median of $4.0 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets skyrocketed 2866.22% in 2021, then crashed 94.57% in 2022.
  • Year by year, Other Non-Current Assets stood at $2.9 million in 2021, then surged by 36.41% to $4.0 million in 2022, then grew by 2.55% to $4.1 million in 2023, then rose by 16.44% to $4.7 million in 2024, then decreased by 16.79% to $3.9 million in 2025.
  • Business Quant data shows Other Non-Current Assets for AGIO at $3.9 million in Q4 2025, $3.9 million in Q3 2025, and $3.9 million in Q2 2025.